Akèy › Skleroz Miltip › Maryland › Baltimore
Etid klinik pou Skleroz Miltip nan Baltimore, MD
7 etid pou Skleroz Miltip ap chèche patisipan nan sit nan ak bò kote Baltimore (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Ap rekriteEtid obsèvasyon
- TG Therapeutics Investigational Trial Site, Baltimore
- TG Therapeutics Investigational Trial Site, Glen Burnie · 9 mi lwen
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Ap rekriteFaz 3
- Baltimore Veterans Affairs Medical Center- Site Number : 8400163, Baltimore
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Ap rekriteFaz 2
- Sheppard Pratt, Towson · 8 mi lwen
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Ap rekriteFaz 2
- Johns Hopkins University, Baltimore
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Ap rekriteFaz 2
- Johns Hopkins University, Baltimore
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Ap rekriteFaz 4
- Johns Hopkins University, Baltimore
Etid Skleroz Miltip nan lòt vil
- New York City, NY17 etid
- Chicago, IL15 etid
- Boston, MA14 etid
- Washington, DC13 etid
- Cleveland, OH9 etid
- St. Louis, MO8 etid
- Kansas City, KS8 etid
- Birmingham, AL8 etid
- San Francisco, CA8 etid
- Aurora, CO7 etid
- Columbus, OH7 etid
- Houston, TX6 etid
Lòt etid nan Baltimore
- Kansè Poumon ki pa ti selil60 etid
- Kansè nan tete47 etid
- Kansè pwostat42 etid
- Kansè poumon40 etid
- Kansè (tout kalite)37 etid
- Kansè pankreyas32 etid
- Kansè kolorektal31 etid
- Kansè Metastatik28 etid
- Obèsite25 etid
- Kansè vejik24 etid
- Ensifizyans kadyak24 etid
- Akidan serebavaskilè22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.